Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...
An FDA Advisory Committee on Thursday voted against broader use of immune checkpoint inhibitors Keytruda and Opdivo developed by Merck (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY) in certain ...
We recently compiled a list of the 8 Dividend Giants with Lowest Short Interest in 2024. In this article, we are going to ...
KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company ...
2seventy bio and Bristol Myers Squibb are pulling the plug on a late-stage study of their Abecma gene therapy in certain people newly diagnosed with the blood cancer multiple myeloma. 2seventy on ...